(3R,5S,7R,8R,9S,10S,12S,13S,14S,17S)-10,13-dimethyl-17-(2-methyl-1,3-dioxolan-2-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol | 222021-98-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (3R,5S,7R,8R,9S,10S,12S,13S,14S,17S)-10,13-dimethyl-17-(2-methyl-1,3-dioxolan-2-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol
• CAS: 222021-98-9
• 化学式: C₂₃H₃₈O₅
• 分子量: 394.552
• InChiKey: ICXNQTLREHVSDR-NUQYUCKASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  28
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  79.2
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (3R,5S,7R,8R,9S,10S,12S,13S,14S,17S)-10,13-dimethyl-17-(2-methyl-1,3-dioxolan-2-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol 在 sodium hydroxide 、 disodium hydrogenphosphate 、 9-borabicyclo[3.3.1]nonane dimer 、 sodium azide 、 urea-hydrogen peroxide 、 双氧水 、 4-甲基苯磺酸吡啶 、 sodium hydride 、 三乙胺 、 三氟乙酸酐 作用下， 以 甲醇 、 二氯甲烷 、 二甲基亚砜 、 丙酮 为溶剂， 反应 173.67h， 生成 (3R,5S,7R,8R,9S,10S,12S,13S,14S,17S)-3,7,12-Tris-(3-azido-propoxy)-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-ol
  参考文献：
  名称：

  Incremental Conversion of Outer-Membrane Permeabilizers into Potent Antibiotics for Gram-Negative Bacteria

  摘要：

  Cholic acid derivatives appended with amine groups have been prepared for use as permeabilizers of the outer membranes of Gram-negative bacteria. These compounds interact synergistically with antibiotics such as erythromycin and novobiocin to inhibit growth of Gram-negative bacteria. When a hydrophobic chain is included on the permeabilizers, they can be converted into potent antibiotics. The role of the hydrophobic chain is to facilitate self-promoted transport of the cholic acid derivatives across the outer membrane of Gramnegative bacteria. These compounds share activities found with polymyxin B and derivatives.

  DOI：

  10.1021/ja982938m
• 作为产物：
  描述：

  Acetic acid (3R,5S,7R,8R,9S,10S,12S,13S,14S,17S)-3,7-diacetoxy-10,13-dimethyl-17-(2-methyl-[1,3]dioxolan-2-yl)-hexadecahydro-cyclopenta[a]phenanthren-12-yl ester 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 24.0h， 以96%的产率得到(3R,5S,7R,8R,9S,10S,12S,13S,14S,17S)-10,13-dimethyl-17-(2-methyl-1,3-dioxolan-2-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol
  参考文献：
  名称：

  Cationic Steroid Microbial Compositions and Methods of Use

  摘要：

  该发明涉及减少或抑制体外、体内或体外细胞的流感病毒感染或发病机制，体外、体内或体外与流感感染或发病机制相关的症状或病理学，或体外、体内或体外流感感染或发病机制的不良副作用的方法。在一种实施方式中，该发明的方法包括使用一种发明化合物（例如，阳离子类固醇抗微生物药物或CSA）治疗受试者。

  公开号：

  US20070191322A1

文献信息

• Cationic Steroid Antimicrobial Compositions and Methods of Use
  申请人：Savage B. Paul

  公开号：US20070190067A1

  公开（公告）日：2007-08-16

  The invention provides methods for decreasing or inhibiting human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) in vitro, ex vivo or in vivo, or an adverse side effect of human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).

  这项发明提供了用于在体外、体外或体内减少或抑制人类免疫缺陷病毒（HIV）感染或病理发生（例如，疾病）、在体外、体外或体内与人类免疫缺陷病毒（HIV）感染或病理发生（例如，疾病）相关的症状或病理、或在体外、体外或体内人类免疫缺陷病毒（HIV）感染或病理发生（例如，疾病）的不良副作用的方法。在一种实施方式中，该发明的方法包括使用一种发明化合物（例如，阳离子类固体抗菌剂或CSA）治疗受试者。
• [EN] CATIONIC STEROID ANTIMICROBIAL DIAGNOSTIC, DETECTION, SCREENING AND IMAGING METHODS<br/>[FR] PROCÉDÉS DE DIAGNOSTIC, DE DÉTECTION, DE TRI ET D'IMAGERIE DE STÉROÏDES CATIONIQUES ANTIMICROBIENS
  申请人：UNIV BRIGHAM YOUNG

  公开号：WO2010036427A1

  公开（公告）日：2010-04-01

  The invention relates to diagnostic, detection, screening and imaging methods. In various embodiments, methods of diagnosis, detection, screening and imaging include administering a cationic steroid antimicrobial or CSA to a subject having or at risk of having an infection or a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in an amount effective to diagnose or detect the infection or the hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject. In a particular aspect, a detectable CSA, namely CSA- 13 labeled with 99mTc is used to detect the presence of an infection.

  该发明涉及诊断、检测、筛查和成像方法。在各种实施方式中，诊断、检测、筛查和成像的方法包括向患有感染或有感染风险的受试者施用阳离子类固醇抗菌药物或CSA，以有效诊断或检测受试者体内的感染或过度增殖疾病（例如肿瘤、癌症或新生物）。在一个特定方面，一种可检测的CSA，即用99mTc标记的CSA-13，被用于检测感染的存在。
• Steroid derived antibiotics
  申请人：Brigham Young University

  公开号：US06350738B1

  公开（公告）日：2002-02-26

  A series of novel steroid derivatives are described. The steroid derivatives are antibacterial agents. The steroid derivatives also act to sensitize bacteria to other antibiotics including erythromycin and novobiocin.

  一系列新型类固醇衍生物被描述。这些类固醇衍生物是抗菌剂。这些类固醇衍生物还能增加细菌对其他抗生素的敏感性，包括红霉素和新霉素。
• US7598234B2
  申请人：——

  公开号：US7598234B2

  公开（公告）日：2009-10-06